Dual immune checkpoint inhibitors (the combination of anti-PD-1 and anti-CTLA-4 therapy) is considered as a promising therapy to enhance ICI efficacy and showed improved prognosis in melanoma and NSCLC (139, 197). Here, PDCD1 is linked to non-small cell lung carcinoma.